Lung cancer: open trials in Netherlands

141 open trials have a site in Netherlands. Registry data; only the trial team decides who can take part.

NCT05384626
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Trial Treatment · Phase 1/2 · Nuvalent Inc.
Netherlands Cancer Institute, Amsterdam · Universitair Medisch Centrum Groningen, Groningen
Registry updated 2026-11-06
NCT05920356
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Trial Treatment · Phase 3 · Amgen
Meander Medisch Centrum Stichting, Amersfoort · University Medical Center Groningen, Groningen · Ziekenhuis St Jansdal, Harderwijk · University Hospital Maastricht, Maastricht · Radboud universitair medisch centrum Stichting, Nijmegen · St. Elisabeth Hospital Tilburg, Tilburg · Isala Klinieken Stichting, Zwolle
Registry updated 2026-11-06
NCT06284317
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
Trial Treatment · Phase 3 · ETOP IBCSG Partners Foundation
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam · Universitair Medisch Centrum Utrecht, Utrecht
Registry updated 2026-11-06
NCT06881784
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Trial Treatment · Phase 3 · Revolution Medicines, Inc.
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam · Amsterdam UMC Stichting, Amsterdam · Universitair Medisch Centrum Groningen, Groningen · Academisch Ziekenhuis Maastricht, Maastricht · Radboud universitair medisch centrum Stichting, Nijmegen · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam
Registry updated 2026-11-06
NCT05789082
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Trial Treatment · Phase 1/2 · Hoffmann-La Roche
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam · Radboud Universitair Medisch Centrum (Radboudumc), Nijmegen
Registry updated 2026-11-05
NCT06793215
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Trial Treatment · Phase 3 · Hoffmann-La Roche
Meander Medisch Centrum, Amersfoort · NKI The Netherlands Cancer Institute, Amsterdam · Ziekenhuis Rijnstate, Arnhem · Amphia Ziekenhuis, Breda · Ziekenhuis St Jansdal, Harderwijk · Medisch Centrum Haaglanden, locatie Antoniushove, Leidschendam · Isala, Zwolle
Registry updated 2026-11-05
NCT07144280
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 3 · Pfizer
Amsterdam UMC Stichting, Amsterdam · Academisch Ziekenhuis Maastricht, Maastricht · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam · St Antonius Ziekenhuis, Utrecht
Registry updated 2026-11-05
NCT07361497
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Trial Treatment · Phase 3 · Bristol-Myers Squibb
Amsterdam UMC Stichting, Amsterdam · Amphia Hospital, Breda · Universitair Medisch Centrum Groningen, Groningen · Radboud universitair medisch centrum Stichting, Nijmegen · Isala Klinieken Stichting, Zwolle
Registry updated 2026-11-05
NCT07519655
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Trial Treatment · Phase 1 · Pfizer
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL), Amsterdam
Registry updated 2026-11-05
NCT06119581
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Trial Treatment · Phase 3 · Eli Lilly and Company
Medisch Spectrum Twente, Enschede · Ziekenhuis St Jansdal, Harderwijk · Tergooiziekenhuizen, Hilversum · Frisius MC, Leeuwarden · Academisch Ziekenhuis Leiden, Leiden · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam · Jeroen Bosch Ziekenhuis, 's-Hertogenbosch · St. Elisabeth Hospital Tilburg, Tilburg · St Antonius Ziekenhuis, Utrecht
Registry updated 2026-11-04
NCT06452277
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 3 · Bayer
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam
Registry updated 2026-11-04
NCT06890598
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Trial Treatment · Phase 3 · Eli Lilly and Company
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL), Amsterdam · Amsterdam UMC Locatie VUMC, Amsterdam · Amphia Ziekenhuis - Locatie Breda Molengracht, Breda · Ziekenhuis St Jansdal, Harderwijk · Maastricht UMC, Maastricht · ETZ Elisabeth, Tilburg · St. Antonius Ziekenhuis, locatie Utrecht, Utrecht · Isala, locatie Zwolle, Zwolle
Registry updated 2026-11-04
2022-502959-54-00
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Trial Treatment · Phase 3 · Dizal Pharmaceutical Co. Ltd.
Academisch Ziekenhuis Maastricht, Maastricht
Registry updated 2026-11-03
NCT03340506
Dabrafenib and/or Trametinib Rollover Study
Trial Treatment · Phase 4 · Novartis Pharmaceuticals
Universitair Medisch Centrum Utrecht, Utrecht
Registry updated 2026-11-03
NCT06170788
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Amphia Hospital, Breda · St. Elisabeth Hospital Tilburg, Tilburg · Isala Klinieken Stichting, Zwolle
Registry updated 2026-11-03
NCT06667908
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 2 · Johnson & Johnson Enterprise Innovation Inc.
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam · Radboud universitair medisch centrum Stichting, Nijmegen
Registry updated 2026-11-03
NCT07288177
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Trial Treatment · Phase 2 · Genmab
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam · Leids Universitair Medisch Centrum (LUMC), Leiden · Radboud universitair medisch centrum Stichting, Nijmegen · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam
Registry updated 2026-11-03
NCT07365319
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Trial Treatment · Phase 2/3 · Eikon Therapeutics
Leids Universitair Medisch Centrum (LUMC), Leiden
Registry updated 2026-11-03
NCT05748093
OSIBOOST 2: Improving Osimertinib cost-effectiveness in Non-Small Cell Lung Cancer treatment using dose-modification and pharmacokinetic boosting with cobicistat or ritonavir
Trial Treatment · Phase 2 · University Hospital Maastricht
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam · Zuyderland Medisch Centrum Stichting, Geleen · Universitair Medisch Centrum Groningen, Groningen · University Hospital Maastricht, Maastricht · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam
Registry updated 2026-11-02
NCT07195695
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Trial Treatment · Phase 3 · Boehringer Ingelheim
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam
Registry updated 2026-11-02
NCT07554339
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Ziekenhuisgroep Twente Stichting, Almelo · Rijnstate Ziekenhuis Stichting, Arnhem · Universitair Medisch Centrum Groningen, Groningen · Leids Universitair Medisch Centrum (LUMC), Leiden · Radboud universitair medisch centrum Stichting, Nijmegen
Registry updated 2026-11-02
NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Trial Treatment · Phase 2/3 · Mirati Therapeutics Inc.
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam · Albert Schweitzer Ziekenhuis, Dordrecht · Ziekenhuis St Jansdal, Harderwijk · Radboud universitair medisch centrum Stichting, Nijmegen · Sint Franciscus Vlietland Groep Stichting, Schiedam · Haga Hospital, 's-Gravenhage
Registry updated 2026-10-30
NCT06043817
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Trial Treatment · Phase 1/2 · Pierre Fabre Medicament
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam
Registry updated 2026-10-30
NCT06623422
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Meander Medisch Centrum Stichting, Amersfoort · Universitair Medisch Centrum Groningen, Groningen · Medisch Centrum Leeuwarden B.V., Leeuwarden · Academisch Ziekenhuis Maastricht, Maastricht · Stichting Radboud Universitair Medisch Centrum, Nijmegen · Jeroen Bosch Ziekenhuis Stichting, 'S-Hertogenbosch · Isala Klinieken Stichting, Zwolle
Registry updated 2026-10-30
NCT07513376
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Meander Medisch Centrum, Amersfoort · Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam · Universitair Medisch Centrum Groningen, Groningen · Ziekenhuis St Jansdal, Harderwijk · Frisius MC, Leeuwarden · Radboud universitair medisch centrum Stichting, Nijmegen · Stichting Elisabeth-TweeSteden Ziekenhuis, Tilburg · Isala Klinieken Stichting, Zwolle
Registry updated 2026-10-30

All Lung cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error